Table 2. Characteristics of excluded studies.

Motta 2011 [80]	Alternating allocation system
Soto 2009 [78]	Extended follow-up period of another trial; Authors re-treated the patients who initially failed treatment with 6 weeks of therapy, and treated 21 new patients with 6 weeks of therapy.
Sousa 2011 [79]	Not randomized trial
Llanos-Cuentas 2010 [82]	Evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis.
Nascimento E 2010 [83]	Evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis.
Garcia 2009 [84]	Conference publication of López-Jaramillo 2010 RCT